Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has granted fast track designation to VIR-5500, an investigational PSMA-targeted T-cell engager, for late-line metastatic castration-resistant prostate cancer (mCRPC). Early phase 1 data look promising — 82% of evaluable patients saw PSA drops of ≥50%, and the overall response rate hit 45%. Phase 3 trials are expected to kick off in 2027.
The FDA has granted fast track designation to VIR-5500 (AMX-500), an investigational PSMA-targeted, dual-masked T-cell engager developed by Vir Biotechnology and Astellas Pharma, for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). The designation reflects the drug's potential to address a serious unmet need in a patient population that has exhausted standard treatment options.
VIR-5500 uses a novel PRO-XTEN masking platform designed to limit activity outside the tumor microenvironment — only activating when tumor-associated proteases cleave its masks, directing T cells to attack PSMA-expressing cancer cells. The drug is currently being evaluated in an ongoing phase 1 trial, with dose-expansion cohorts launched in April 2026. Phase 3 trials are anticipated to begin in 2027.
By the Numbers:
Why it matters: Advanced prostate cancer patients who've progressed through androgen signaling inhibitors and taxanes have very limited options. VIR-5500's tumor-selective mechanism and early efficacy signals make it a potentially meaningful addition to the mCRPC treatment landscape — and the FDA's fast track status could accelerate its path to approval.
